The Effect of Access Restrictions on the Vintage of Drugs Used by Medicaid Enrollees

Graduate School of Business, Columbia University, New York, NY 10027, USA.
The American journal of managed care (Impact Factor: 2.26). 02/2005; 11 Spec No:SP7-13.
Source: PubMed


To examine the extent to which recent Medicaid drug access restrictions, such as preferred drug lists (PDLs), may affect the vintage (or time since Food and Drug Administration approval) of 6 types of drugs used by Medicaid beneficiaries.
Retrospective claims database analysis using National Drug Code pharmacy claims data.
A regression model was developed to analyze the effect that Medicaid access restrictions had on the vintage of medications prescribed in 6 different therapeutic categories. A "difference in differences" approach was used to compare the change in vintage of medications prescribed in Medicaid versus non-Medicaid patients between the January-June 2001 and July-December 2003 study periods.
The results of the regression model showed that PDLs increased the age of Medicaid prescriptions by less than 1 year for drugs in 5 of the 6 therapeutic classes analyzed. In the case of pain management medications, the increase was more than 1.2 years.
The results of the regression model suggest that Medicaid drug access restriction programs (e.g., PDLs) have resulted in an increase in the age of drugs prescribed for Medicaid beneficiaries versus non-Medicaid patients. Since previous research has suggested a clinical and economic advantage to utilizing newer versus older drugs, further research should be conducted to explore how these medication restriction policies may unduly affect Medicaid beneficiaries compared with privately insured patients.

Download full-text


Available from: Frank Lichtenberg, Dec 27, 2013
  • Source
    • "To further illustrate that prescription drugs are one of the most effective and least expensive segment in healthcare, Lichtenberg (2005), as mentioned in Bussing-Burks (2006), did a study that indicated that replacing 1000 old prescription drugs with 1000 new prescription drugs resulted in drug costs increasing by $18,000 with hospital costs decreasing by $44,469. Lichtenberg’s data was obtained via the 1996 Medical Expenditure Panel Survey. "
    [Show abstract] [Hide abstract]
    ABSTRACT: To analyze the implementation of Medicaid preferred drug lists (PDLs) in a number of states and determine its impact on quality of care and cost relative to other segments of healthcare. We reviewed research and case studies found by searching library databases, primarily MEDLINE and EBSCOHost, and searching pertinent journals. Keywords initially included "drug lists," "prior authorization," "prior approval," and "Medicaid." We added terms such as "influence use of other healthcare services," "quality of care," and "overall economic impact." We mainly used primary sources. Based on our literature review, we determined that there are a number of issues regarding Medicaid PDLs that need to be addressed. Some issues include: (a) the potential for PDLs to influence the utilization of other healthcare services, (b) criteria used by Medicaid for determining acceptance of drugs onto a PDL, (c) the effect of PDL implementation on compliance to new regimens, (d) the potential effects of restricting medication availability on quality of care, (e) administrative costs associated with PDLs, and (f) satisfaction rates among patients and medical providers. This review highlighted expected short-term cost savings with limited degree of compromised quality of PDL implementation, but raised the concern about the potential long-term decline in quality of care and overall economic impact. The number of concerns raised indicates that further studies are warranted regarding both short-term cost benefits as well as potential long-term effects of Medicaid PDL implementation. Objective analysis of these effects is necessary to ensure cost-effectiveness and quality of care.
    Full-text · Article · Feb 2008 · Vascular Health and Risk Management
  • [Show abstract] [Hide abstract]
    ABSTRACT: To test the hypothesis that, ceteris paribus, people using newer, or later vintage drugs will be in better health, and will therefore be less likely to be admitted to hospitals and nursing homes, by examining the effect of pharmaceutical innovation on the utilisation of hospital and long-term care by elderly Americans during 1997-2003. An estimation of difference-in-differences models of hospital discharge rates using longitudinal state-level data on 12 states. Data on the utilisation of over 43 000 products, by state and year, were obtained from state Medicaid agencies. The extent of utilisation of new drugs in the Medicaid programme is strongly correlated with the extent of utilisation of new drugs in general. PATIENTS OR STUDY PARTICIPANTS: All elderly residents of 12 states during the period 1997-2003. The relative utilisation of new and old drugs. Discharges per elderly individual, discharges to nursing homes per elderly individual, and inpatient deaths per elderly individual. States that had larger increases in drug vintage had smaller increases in the number of hospital discharges per elderly individual. They also had smaller increases in the number of hospital discharges to nursing homes and the number of in-hospital deaths per elderly individual. Even the upper-bound estimate of the increase in 2003 drug expenditure attributable to the 1997-2003 increase in drug vintage is lower than the sum of the lowest estimates of the 2003 hospital and nursing home expenditure reductions attributable to the 1997-2003 increase in drug vintage.
    No preview · Article · Feb 2006 · PharmacoEconomics
  • Source
    Full-text · Article · Feb 2006
Show more